Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials

Margery Gass, Joseph Larson, Barbara Cochrane, Joann E. Manson, Dorothy Lane, Vanessa Barnabei, Judith Ockene, Marcia L. Stefanick, Charles Mouton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative. Methods: Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables. Results: In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0% vs 34.2%; P = 0.37). Sexual activity of former ET users was 5.6% higher than placebo users (27.6% vs 22.0%; P = 0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10% to 12% more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P < 0.001). Former ET users were more likely than placebo users to report rare to no desire or arousal postintervention (P < 0.001). Conclusions: Postintervention ET trial participants formerly assigned to ET were significantly more likely to report sexual activity than those formerly assigned to placebo. Women who discontinued EPT were significantly more likely to report negative vaginal and sex-related effects.

Original languageEnglish (US)
Pages (from-to)252-264
Number of pages13
JournalMenopause
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Women's Health
Sexual Behavior
Hormones
Estrogens
Progestins
Placebos
Therapeutics
Arousal
Orgasm
Dyspareunia
Chi-Square Distribution
Hysterectomy
Uterus

Keywords

  • Genitourinary syndrome of menopause
  • Hormone therapy discontinuation
  • Sexual function

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. / Gass, Margery; Larson, Joseph; Cochrane, Barbara; Manson, Joann E.; Lane, Dorothy; Barnabei, Vanessa; Ockene, Judith; Stefanick, Marcia L.; Mouton, Charles.

In: Menopause, Vol. 25, No. 3, 01.03.2018, p. 252-264.

Research output: Contribution to journalArticle

Gass, M, Larson, J, Cochrane, B, Manson, JE, Lane, D, Barnabei, V, Ockene, J, Stefanick, ML & Mouton, C 2018, 'Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials', Menopause, vol. 25, no. 3, pp. 252-264. https://doi.org/10.1097/GME.0000000000000994
Gass, Margery ; Larson, Joseph ; Cochrane, Barbara ; Manson, Joann E. ; Lane, Dorothy ; Barnabei, Vanessa ; Ockene, Judith ; Stefanick, Marcia L. ; Mouton, Charles. / Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. In: Menopause. 2018 ; Vol. 25, No. 3. pp. 252-264.
@article{2a2a95d5d37e4730a1f1414f39a58e73,
title = "Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials",
abstract = "Objective: To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative. Methods: Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables. Results: In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0{\%} vs 34.2{\%}; P = 0.37). Sexual activity of former ET users was 5.6{\%} higher than placebo users (27.6{\%} vs 22.0{\%}; P = 0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10{\%} to 12{\%} more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P < 0.001). Former ET users were more likely than placebo users to report rare to no desire or arousal postintervention (P < 0.001). Conclusions: Postintervention ET trial participants formerly assigned to ET were significantly more likely to report sexual activity than those formerly assigned to placebo. Women who discontinued EPT were significantly more likely to report negative vaginal and sex-related effects.",
keywords = "Genitourinary syndrome of menopause, Hormone therapy discontinuation, Sexual function",
author = "Margery Gass and Joseph Larson and Barbara Cochrane and Manson, {Joann E.} and Dorothy Lane and Vanessa Barnabei and Judith Ockene and Stefanick, {Marcia L.} and Charles Mouton",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/GME.0000000000000994",
language = "English (US)",
volume = "25",
pages = "252--264",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials

AU - Gass, Margery

AU - Larson, Joseph

AU - Cochrane, Barbara

AU - Manson, Joann E.

AU - Lane, Dorothy

AU - Barnabei, Vanessa

AU - Ockene, Judith

AU - Stefanick, Marcia L.

AU - Mouton, Charles

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative. Methods: Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables. Results: In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0% vs 34.2%; P = 0.37). Sexual activity of former ET users was 5.6% higher than placebo users (27.6% vs 22.0%; P = 0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10% to 12% more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P < 0.001). Former ET users were more likely than placebo users to report rare to no desire or arousal postintervention (P < 0.001). Conclusions: Postintervention ET trial participants formerly assigned to ET were significantly more likely to report sexual activity than those formerly assigned to placebo. Women who discontinued EPT were significantly more likely to report negative vaginal and sex-related effects.

AB - Objective: To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative. Methods: Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables. Results: In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0% vs 34.2%; P = 0.37). Sexual activity of former ET users was 5.6% higher than placebo users (27.6% vs 22.0%; P = 0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10% to 12% more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P < 0.001). Former ET users were more likely than placebo users to report rare to no desire or arousal postintervention (P < 0.001). Conclusions: Postintervention ET trial participants formerly assigned to ET were significantly more likely to report sexual activity than those formerly assigned to placebo. Women who discontinued EPT were significantly more likely to report negative vaginal and sex-related effects.

KW - Genitourinary syndrome of menopause

KW - Hormone therapy discontinuation

KW - Sexual function

UR - http://www.scopus.com/inward/record.url?scp=85042452604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042452604&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000994

DO - 10.1097/GME.0000000000000994

M3 - Article

VL - 25

SP - 252

EP - 264

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 3

ER -